Literature DB >> 21372565

Longitudinal hemodiafilter performance in modeled continuous renal replacement therapy.

Deborah A Pasko1, Mariann D Churchwell, Noha N Salama, Bruce A Mueller.   

Abstract

BACKGROUND/AIMS: With advanced anticoagulation, many institutions operate continuous renal replacement therapy (CRRT) circuits longer than manufacturers' recommendations. This extended use may change hemodiafilter performance and clearance properties. However, hemodiafilter performance over time has not been assessed. We investigated solute clearance over time in modeled CRRT.
METHODS: In vitro continuous hemofiltration (CH) and continuous hemodialysis (CD) were operated for 48 h using AN69 polyacrylonitrile, cellulose triacetate, F70 polysulfone, and Optiflux F160NR polysulfone hemodiafilters with citrated bovine blood. Urea, creatinine, gentamicin, vancomycin, and albumin clearances were assessed in CH (ultrafiltration rates = 1 and 3 l/h). Clearances of urea, creatinine, gentamicin, and albumin, were assessed in CD with dialysate flow rate of 2 l/h.
RESULTS: Solute CH clearances were significantly higher at 3 l/h. Only creatinine and gentamicin clearances were affected by time. Creatinine CD clearance significantly declined at 48 h for all hemodiafilters, especially polysulfone hemodiafilters.
CONCLUSIONS: CRRT duration affects solute transmembrane clearance. Clinicians should consider hemodiafilter age when assessing hemodialysis dose or drug clearance.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21372565      PMCID: PMC3064935          DOI: 10.1159/000324191

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  20 in total

1.  Hemofiltration treatment for sepsis: is it time for controlled trials?

Authors:  P Rogiers
Journal:  Kidney Int Suppl       Date:  1999-11       Impact factor: 10.545

2.  Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution.

Authors:  Shigehiko Uchino; Louise Cole; Hiroshi Morimatsu; Donna Goldsmith; Rinaldo Bellomo
Journal:  Intensive Care Med       Date:  2002-11       Impact factor: 17.440

3.  Efficacy of convective removal of plasma mediators of endotoxic shock by continuous veno-venous hemofiltration.

Authors:  G Bottoms; J Fessler; E Murphey; M Johnson; H Latshaw; B Mueller; W Clark; W Macias
Journal:  Shock       Date:  1996-02       Impact factor: 3.454

4.  A comparison of metabolic control by continuous and intermittent therapies in acute renal failure.

Authors:  W R Clark; B A Mueller; K J Alaka; W L Macias
Journal:  J Am Soc Nephrol       Date:  1994-01       Impact factor: 10.121

5.  Anticoagulation in patients treated by continuous venovenous hemofiltration: a retrospective study.

Authors:  P Y Martin; J C Chevrolet; P Suter; H Favre
Journal:  Am J Kidney Dis       Date:  1994-11       Impact factor: 8.860

6.  Higher renal replacement therapy dose delivery influences on drug therapy.

Authors:  Bruce A Mueller; Deborah A Pasko; Kevin M Sowinski
Journal:  Artif Organs       Date:  2003-09       Impact factor: 3.094

7.  Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients.

Authors:  R Bellomo; P Tipping; N Boyce
Journal:  Crit Care Med       Date:  1993-04       Impact factor: 7.598

8.  Ertapenem clearance during modeled continuous renal replacement therapy.

Authors:  J M Stevenson; J H Patel; M D Churchwell; A M Vilay; D D Depestel; F Sörgel; M Kinzig; V Jakob; B A Mueller
Journal:  Int J Artif Organs       Date:  2008-12       Impact factor: 1.595

9.  Plasma protein adsorption to highly permeable hemodialysis membranes.

Authors:  W R Clark; W L Macias; B A Molitoris; N H Wang
Journal:  Kidney Int       Date:  1995-08       Impact factor: 10.612

10.  Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation.

Authors:  R Swartz; D Pasko; J O'Toole; B Starmann
Journal:  Clin Nephrol       Date:  2004-02       Impact factor: 0.975

View more
  5 in total

Review 1.  A Guide to Understanding Antimicrobial Drug Dosing in Critically Ill Patients on Renal Replacement Therapy.

Authors:  Valentina Pistolesi; Santo Morabito; Francesca Di Mario; Giuseppe Regolisti; Chiara Cantarelli; Enrico Fiaccadori
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Reply to Baud and Houzé, "Should In Vitro and In Vivo Studies on Antimicrobial Agents during Continuous Renal Replacement Therapy Comply with General Principles of Pharmacokinetics?"

Authors:  E Wenzler; M Biagi; X Tan; D A Butler
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

Review 3.  Renal replacement therapy: a practical update.

Authors:  George Alvarez; Carla Chrusch; Terry Hulme; Juan G Posadas-Calleja
Journal:  Can J Anaesth       Date:  2019-02-06       Impact factor: 5.063

4.  A mode of CVVH with regional citrate anticoagulation compared to no anticoagulation for acute kidney injury patients at high risk of bleeding.

Authors:  Jianping Gao; Feng Wang; Yonggang Wang; Dan Jin; Liping Tang; Konghan Pan
Journal:  Sci Rep       Date:  2019-04-29       Impact factor: 4.379

5.  Clinical Validation of Therapeutic Drug Monitoring of Imipenem in Spent Effluent in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot Study.

Authors:  Aiping Wen; Zhe Li; Junxian Yu; Ren Li; Sheng Cheng; Meili Duan; Jing Bai
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.